메뉴 건너뛰기




Volumn 18, Issue 4, 2012, Pages 501-507

Investigation and threshold of optimum blood concentration of voriconazole: A descriptive statistical meta-analysis

Author keywords

Blood concentration; Meta analysis; Therapeutic drug monitoring; Voriconazole

Indexed keywords

VORICONAZOLE;

EID: 84865137573     PISSN: 1341321X     EISSN: 14377780     Source Type: Journal    
DOI: 10.1007/s10156-011-0363-6     Document Type: Article
Times cited : (95)

References (25)
  • 1
    • 0031974507 scopus 로고    scopus 로고
    • In vitro activity of the new triazole voriconazole (UK-109, 494) against opportunistic filamentous and dimorphic fungiand common and emerging pathogens
    • A Epinel-Ingroff 1998 In vitro activity of the new triazole voriconazole (UK-109, 494) against opportunisticfilamentous and dimorphic fungi and common and emerging pathogens J Clin Microbiol 36 198 202
    • (1998) J Clin Microbiol , vol.36 , pp. 198-202
    • Epinel-Ingroff, A.1
  • 2
    • 84871365024 scopus 로고    scopus 로고
    • Deep-Seated Mycosis Guidelines Editorial Committee Tokyo: Kyowakikaku (in Japanese)
    • Deep-Seated Mycosis Guidelines Editorial Committee. Guidelines for management of deep-seated mycosis 2007. Tokyo:Kyowakikaku; 2007 (in Japanese).
    • (2007) Guidelines for Management of Deep-seated Mycosis 2007
  • 3
    • 37549028402 scopus 로고    scopus 로고
    • Antifungal serum concentration monitoring: An update
    • 17999982 10.1093/jac/dkm389 1:CAS:528:DC%2BD1cXhtFWlsA%3D%3D
    • ML Goodwin RH Drew 2008 Antifungal serum concentration monitoring: an update J Antimicrob Chemother 61 17 25 1799998210.1093/jac/dkm389 1:CAS:528:DC%2BD1cXhtFWlsA%3D%3D
    • (2008) J Antimicrob Chemother , vol.61 , pp. 17-25
    • Goodwin, M.L.1    Drew, R.H.2
  • 4
    • 0141925590 scopus 로고    scopus 로고
    • In vivo pharmacokinetics and pharmacodynamics of a new triazole, voriconazole, in a murine candidiasis model
    • DOI 10.1128/AAC.47.10.3165-3169.2003
    • D Andes K Marchillo T Stamstad R Conklin 2003 In vivo pharmacokinetics and pharmacodynamics of a new triazole,voriconazole, in a murine candidiasis model Antimicrob Agents Chemother 47 3165 3169 1450602610.1128/AAC.47.10.3165- 3169.2003 1:CAS:528:DC%2BD3sXnvVWmtr8%3D (Pubitemid 37229574)
    • (2003) Antimicrobial Agents and Chemotherapy , vol.47 , Issue.10 , pp. 3165-3169
    • Andes, D.1    Marchillo, K.2    Stamstad, T.3    Conklin, R.4
  • 5
    • 29644443880 scopus 로고    scopus 로고
    • Pharmacokinetics of voriconazole
    • N Wood 2005 Pharmacokinetics of Voriconazole Jpn J Chemother 53 16 23 1:CAS:528:DC%2BD28XjvFaruw%3D%3D (Pubitemid43019838)
    • (2005) Japanese Journal of Chemotherapy , vol.53 , Issue.SUPPL. 2 , pp. 16-23
    • Wood, N.1
  • 6
    • 60549086769 scopus 로고    scopus 로고
    • The CYP2C19 ultra-rapid metabolizer genotype influences the pharmacokinetics of voriconazole in healthy malevolunteers
    • 18982321 10.1007/s00228-008-0574-7 1:CAS:528:DC%2BD1MXitVyiu7s%3D
    • G Wang HP Lei Z Li ZR Tan D Guo L Fan, et al. 2009 The CYP2C19 ultra-rapid metabolizer genotype influences thepharmacokinetics of voriconazole in healthy male volunteers Eur J Clin Pharmacol 65 281 285 1898232110.1007/ s00228-008-0574-7 1:CAS:528:DC%2BD1MXitVyiu7s%3D
    • (2009) Eur J Clin Pharmacol , vol.65 , pp. 281-285
    • Wang, G.1    Lei, H.P.2    Li, Z.3    Tan, Z.R.4    Guo, D.5    Fan, L.6
  • 8
    • 29644436193 scopus 로고    scopus 로고
    • Antifungal activity of voriconazole
    • H Yamaguchi 2005 Antifungal activity of voriconazole Jpn J Chemother 53 8 15 1:CAS:528:DC%2BD28XjvFarug%3D%3D(Pubitemid 43019837)
    • (2005) Japanese Journal of Chemotherapy , vol.53 , Issue.SUPPL. 2 , pp. 8-15
    • Yamaguchi, H.1
  • 9
    • 0030922816 scopus 로고    scopus 로고
    • Bias in meta-analysis detected by a simple, graphical test
    • M Egger SG Davey M Schneider C Minder 1997 Bias in meta-analysis detected by a simple, graphical test BMJ 315 629 6349310563 10.1136/bmj.315.7109.629 1:STN:280:DyaK2svls1KjtA%3D%3D (Pubitemid 27387172)
    • (1997) British Medical Journal , vol.315 , Issue.7109 , pp. 629-634
    • Egger, M.1    Smith, G.D.2    Schneider, M.3    Minder, C.4
  • 10
    • 67349258906 scopus 로고    scopus 로고
    • Correlation between voriconazole trough plasma concentration and hepatotoxicity in patients with different CYP2C19genotypes
    • 19261446 10.1016/j.ijantimicag.2009.01.008 1:CAS:528:DC%2BD1MXmsVShsro%3D
    • K Matsumoto K Ikawa K Abematsu N Fukunaga K Nishida T Fukumizu, et al. 2009 Correlation between voriconazole troughplasma concentration and hepatotoxicity in patients with different CYP2C19 genotypes Int J Antimicrob Agents 34 91 9419261446 10.1016/j.ijantimicag.2009.01.008 1:CAS:528: DC%2BD1MXmsVShsro%3D
    • (2009) Int J Antimicrob Agents , vol.34 , pp. 91-94
    • Matsumoto, K.1    Ikawa, K.2    Abematsu, K.3    Fukunaga, N.4    Nishida, K.5    Fukumizu, T.6
  • 11
    • 64849103940 scopus 로고    scopus 로고
    • Usefulness of monitoring plasma voriconazole concentration in patients with chronic necrotizing pulmonaryaspergillosis
    • 19260530
    • E Hagiwara J Shiihara A Matsushima T Enomoto A Tagawa A Sekine, et al. 2009 Usefulness of monitoring plasmavoriconazole concentration in patients with chronic necrotizing pulmonary aspergillosis Nihon Kokyuki Gakkai Zasshi 47 93 9719260530
    • (2009) Nihon Kokyuki Gakkai Zasshi , vol.47 , pp. 93-97
    • Hagiwara, E.1    Shiihara, J.2    Matsushima, A.3    Enomoto, T.4    Tagawa, A.5    Sekine, A.6
  • 12
    • 67749101112 scopus 로고    scopus 로고
    • Monitoring trough concentration of voriconazole is important to ensure successful antifungal therapy and to avoidhepatic damage in patients with hematological disorders
    • 19340528 10.1007/s12185-009-0296-3 1:CAS:528:DC%2BD1MXms1KksLc%3D
    • K Ueda Y Nannya K Kumano A Hangaishi T Takahashi Y Imai, et al. 2009 Monitoring trough concentration of voriconazoleis important to ensure successful antifungal therapy and to avoid hepatic damage in patients with hematological disorders IntJ Hematol 89 592 599 19340528 10.1007/s12185-009-0296-3 1:CAS:528:DC%2BD1MXms1KksLc%3D
    • (2009) Int J Hematol , vol.89 , pp. 592-599
    • Ueda, K.1    Nannya, Y.2    Kumano, K.3    Hangaishi, A.4    Takahashi, T.5    Imai, Y.6
  • 13
    • 78249234244 scopus 로고    scopus 로고
    • Clinical significance of measuring serum concentrations of voriconazole in the hematological field
    • 10.5649/jjphcs.34.638 1:CAS:528:DC%2BD1cXhtVSgt73J
    • S Shimoeda K Nakazawa H Kobayashi S Nakagawa S Yamato M Sasaki, et al. 2008 Clinical significance of measuring serumconcentrations of voriconazole in the hematological field Jpn J Pharm Health Care Sci 34 638 643 10.5649/jjphcs.34.6381:CAS:528:DC%2BD1cXhtVSgt73J
    • (2008) Jpn J Pharm Health Care Sci , vol.34 , pp. 638-643
    • Shimoeda, S.1    Nakazawa, K.2    Kobayashi, H.3    Nakagawa, S.4    Yamato, S.5    Sasaki, M.6
  • 14
    • 57149104429 scopus 로고    scopus 로고
    • Retrospective serological tests for determining the optimal blood concentration of voriconazole for treating fungalinfection
    • 19043301 10.1248/yakushi.128.1811 1:CAS:528:DC%2BD1MXhtlWisbo%3D
    • T Okuda A Okuda N Watanabe M Takao K Takayanagi 2008 Retrospective serological tests for determining the optimal bloodconcentration of voriconazole for treating fungal infection Yakugaku Zasshi 128 1811 1818 19043301 10.1248/yakushi.128.18111:CAS:528:DC%2BD1MXhtlWisbo%3D
    • (2008) Yakugaku Zasshi , vol.128 , pp. 1811-1818
    • Okuda, T.1    Okuda, A.2    Watanabe, N.3    Takao, M.4    Takayanagi, K.5
  • 15
    • 39449117139 scopus 로고    scopus 로고
    • Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes
    • DOI 10.1086/524669
    • A Pascual T Calandra S Bolay T Buclin J Bille O Marchetti 2008 Voriconazole therapeutic drug monitoring in patientswith invasive mycoses improves efficacy and safety outcomes Clin Infect Dis 46 201 211 18171251 10.1086/5246691:CAS:528:DC%2BD1cXhvVClsbY%3D (Pubitemid 351269158)
    • (2008) Clinical Infectious Diseases , vol.46 , Issue.2 , pp. 201-211
    • Pascual, A.1    Calandra, T.2    Bolay, S.3    Buclin, T.4    Bille, J.5    Marchetti, O.6
  • 16
    • 33845942810 scopus 로고    scopus 로고
    • Neurological adverse events to voriconazole: Evidence for therapeutic drug monitoring
    • A Imhof DJ Schaer U Schanz U Schwarz 2006 Neurological adverse events to voriconazole: evidence for therapeutic drugmonitoring Swiss Med Wkly 136 739 742 17183438 1:CAS:528:DC%2BD2sXhtVOisb0%3D (Pubitemid 46032197)
    • (2006) Swiss Medical Weekly , vol.136 , Issue.45-46 , pp. 739-742
    • Imhof, A.1    Schaer, D.J.2    Schwarz, U.3    Schanz, U.4
  • 17
    • 85030497233 scopus 로고    scopus 로고
    • Zoukishikkan wo Kisosikkan tosita Shinsyusei Aspergillus reiniokeru Voriconazole no Yakubutukettyuunoudo Monitoring toRinsyokouka
    • Y Obata T Takada K Tamura 2008 Zoukishikkan wo Kisosikkan tosita Shinsyusei Aspergillus reiniokeru Voriconazole noYakubutukettyuunoudo Monitoring to Rinsyokouka Jpn J Chemother 56 172
    • (2008) Jpn J Chemother , vol.56 , pp. 172
    • Obata, Y.1    Takada, T.2    Tamura, K.3
  • 21
    • 33645761890 scopus 로고    scopus 로고
    • Voriconazole therapeutic drug monitoring
    • 16569888 10.1128/AAC.50.4.1570-1572.2006 1:CAS:528:DC%2BD28XjvFOrtrg%3D
    • J Smith N Safdar V Knasinski W Simmons SM Bhavnani PG Ambrose, et al. 2006 Voriconazole therapeutic drug monitoringAntimicrob Agents Chemother 50 1570 1572 16569888 10.1128/AAC.50.4.1570-1572.2006 1:CAS:528:DC%2BD28XjvFOrtrg%3D
    • (2006) Antimicrob Agents Chemother , vol.50 , pp. 1570-1572
    • Smith, J.1    Safdar, N.2    Knasinski, V.3    Simmons, W.4    Bhavnani, S.M.5    Ambrose, P.G.6
  • 22
    • 31344478761 scopus 로고    scopus 로고
    • Investigation of the potential relationships between plasma voriconazole concentrations and visual adverse events orliver function test abnormalities
    • DOI 10.1177/0091270005283837
    • K Tan N Brayshaw K Tomaszewski P Troke N Wood 2006 Investigation of the potential relationships between plasmavoriconazole concentrations and visual adverse events or liver function test abnormalities J Clin Pharmacol 46 235 24316432276 10.1177/0091270005283837 1:CAS:528:DC%2BD28XhsFejsb4%3D (Pubitemid 43146453)
    • (2006) Journal of Clinical Pharmacology , vol.46 , Issue.2 , pp. 235-243
    • Tan, K.1    Brayshaw, N.2    Tomaszewski, K.3    Troke, P.4    Wood, N.5
  • 24
    • 4444278991 scopus 로고    scopus 로고
    • The effects of gender, age, ethnicity, and liver cirrhosis on cytochrome P450 enzyme activity in human livermicrosomes and inducibility in cultured human hepatocytes
    • DOI 10.1016/j.taap.2004.01.010, PII S0041008X04000638
    • A Parkinson DR Mudra C Johnson A Dwyer KM Carroll 2004 The effects of gender, age, ethnicity, and liver cirrhosis oncytochrome P450 enzyme activity in human liver microsomes and inducibility in cultured human hepatocytes Toxicol ApplPharmacol 199 193 209 15364537 10.1016/j.taap.2004.01.010 1:CAS:528:DC%2BD2cXnsFGgtbY%3D (Pubitemid 39208721)
    • (2004) Toxicology and Applied Pharmacology , vol.199 , Issue.3 , pp. 193-209
    • Parkinson, A.1    Mudra, D.R.2    Johnson, C.3    Dwyer, A.4    Carroll, K.M.5


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.